c-Kit Mutation Detection Kit
Available Products
| Product Name/Description |
No. of Reactions*
|
Product Code |
|---|---|---|
| c-Kit Mutation Detection Kit for Real-Time PCR |
44
|
CKIT-RT44 |
*Includes all controls.
c-Kit Mutations in Melanoma
KIT mutations are found in approximately five to 30 percent of acral and mucosal melanomas and melanomas arising on chronically sun-damaged skin. Mutations occur primarily in exon 11 and secondarily in exons 13, 17, and 18. The overall response rate to imatinib in KIT-mutated melanoma is 16 to 23 percent, demonstrating the value of KIT-mutation testing in melanoma patients. [1][2][3]
The c-Kit Mutation Detection Kit detects the following mutations:
| Mutation | COSMIC ID |
| EX11_ p.V559D | COSM1252 |
| EX11_p.V559G | COSM1253 |
| EX11_p.V560D | COSM1257 |
| EX11_W557R | COSM1216 |
| EX17_p.D816H | COSM1311 |
| EX17_p.D816V | COSM1314 |
| EX11_p.L576P | COSM1290 |
| EX13_p.K642E | COSM1304 |
| EX9_p.Y503_F504insAY | COSM12444 |
| EX11_p.W557_E561del | COSM18890 |
| EX11_p.W557_K558del | COSM12449 |
| EX11_p.W557_V559>C | COSM1233 |
| EX11_p.W557_V559>F | COSM1226 |
| EX17_p.N822Y | COSM19109 |
| EX17_p.K818R | COSM1315 |
| EX17_p.N822H | COSM1318 |
| EX11_p.V559A | COSM1255 |
| EX11_p.W557G | COSM1221 |
| EX17_p.D820G | COSM1316 |
| EX17_p.D820Y | COSM12710 |
| EX17_p.N822K | COSM1322 |
Testing Procedure and Analysis
EntroGen’s c-Kit Mutation Detection Kit is a polymerase chain reaction (PCR)-based assay that uses allele-specific primers to identify the presence of somatic mutations in c-KIT genes. The testing procedure involves three (3) simple steps:
- Isolation of DNA from tumor biopsies, paraffin-embedded sections (FFPE), or fine needle aspirates (FNA)
- Amplification of regions of the c-KIT genes using allele-specific primers
- Analysis of the captured amplification data.
This test can be completed in approximately 2 hours from isolation of DNA to test result.
Equipment and Materials
EntroGen’s c-Kit Mutation Detection Kit requires a real-time PCR instrument capable of detecting FAM, VIC, ROX and CY5 fluorescent probes.
This test includes reagents required for the PCR amplification/detection, as well as validated reaction controls. Columns and reagents for DNA isolation are not included.
Intended Use
USA:
EntroGen’s Thyroid Cancer Mutation Panel is provided for research use only (RUO). Not for use in diagnostic procedures.
Europe:
EntroGen’s Thyroid Cancer Mutation Panel is available for research (RUO) and diagnostic (CE-IVD) purposes.
[1] Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182-3190.
[2] Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-2334.
[3] Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904-2909.